Loading...
Loading...
Of the 26 tracked institutions holding UNH, 18 have a 3-year clone track record — 13 of them beat the S&P. Average holder's clone alpha: +3.0pt. It's a gauge of who owns the name, not just how many.
Among the 26 tracked institutional investors we monitor, UNH (UNITEDHEALTH GROUP INC) is held with a combined value of $83.59B across 288,785,005 shares. The largest holder is VANGUARD GROUP INC with a position worth $30.24B (0.44% of their portfolio). 2 funds opened new positions in the most recent quarter. 13 funds increased their holdings. 10 funds reduced their position.
Total Institutional Value
$83.59B
Total Shares Held
288,785,005
Institutional Holders
26
% of Shares Outstanding
31.8%
of 908.14M shares · SEC 2026-04-30
Days to Cover
3.5-5.8%
17.34M shares short · FINRA 2026-07-15
Tracked 13F institutions hold 31.8% of UNH's shares outstanding. This is a floor: 13F filings arrive on a ~45-day lag and we track only a subset of institutional filers, so true institutional ownership is higher. Shares-outstanding is the latest SEC cover-page figure (as of 2026-04-30), not a live float.
Ranked by estimated dollars moved (share change × implied price). 13F data lags up to 45 days.
0
$0
1
$284.00K
Total Transactions
1
Last 12 months
| Date | Insider | Code | Type | Shares | Value |
|---|---|---|---|---|---|
| Apr 23, 2026 | Patrick Hugh Conway | S | Sale | 800 | $284.00K |
| # | Fund | Value↓ | Portfolio % | Change |
|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | $30.24B | 0.44% | +1.1% |
| 2 | BlackRock, Inc. | $19.88B | 0.35% | -1.7% |
| 3 | STATE STREET CORP | $12.27B | 0.42% | +0.2% |
| 4 | PRICE T ROWE ASSOCIATES INC /MD/ | $5.65B | 0.65% | +10.9% |
| 5 | Capital Research Global Investors | $4.63B | 0.72% | +173.3% |
| 6 | FMR LLC | $3.25B | 0.17% | -5.4% |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | $2.73B | 0.51% | -35.7% |
| 8 | Fisher Asset Management, LLC | $1.42B | 0.48% | -1.1% |
| 9 | MILLENNIUM MANAGEMENT LLC | $897.71M | 0.37% | +56.4% |
| 10 | Grantham, Mayo, Van Otterloo & Co. LLC | $854.65M | 2.19% | +18.3% |
| Description | Amount |
|---|---|
CHEMOTHERAPY COMPOUNDED DRUG NP | $50K |
PHARMACY COMPOUNDING SERVICES - THREE MONTHS EXTENSION | $150K |
URGENT PROCUREMENT FOR CHEMOTHERAPY COMPOUNDING PHARMACY DRUGS VIA PRICE LIST | $156K |
CONTINGENCY PHARMACY COMPOUNDING PRODUCTS-SERVICES. |
| Member | Type | Date |
|---|---|---|
| Dan Newhouse | Sell | Jul 10, 2026 |
| Richard Dean McCormick | Sell | Jun 12, 2026 |
| Maria Elvira Salazar | Sell | Jun 4, 2026 |
| John Boozman | Buy |
As of the latest SEC 13F filings, VANGUARD GROUP INC is the largest institutional holder of UNH with a position worth $30.24B, representing 0.44% of their portfolio. In total, 26 institutional investors hold UNH with a combined value of $83.59B.
In the most recent quarter, 2 funds opened a new position in UNH. Additionally, 13 increased their holdings and 10 reduced their positions.
Institutional investors hold $83.59B worth of UNH stock across 26 positions. The largest institutional holder is VANGUARD GROUP INC with $30.24B in holdings.
A 13F filing is a quarterly report required by the SEC from institutional investment managers with over $100 million in assets. It discloses their holdings in U.S. equities. For UNH, these filings reveal which major funds are accumulating or reducing positions, providing insights into institutional sentiment.
Get notified when hedge funds change their UNH positions.
Alpha = the manager's 3-year clone return minus the S&P 500. A skilled roster is a stronger tell than a crowded one — though even skilled managers' edge doesn't reliably survive the 13F disclosure lag. Why →
| $150K |
PHARMACY COMPOUNDING SERVICES - THREE MONTHS EXTENSION | — |
PHARMACY COMPOUNDING SERVICE. | $557 |
EXPRESS REPORT: R1 FY26 1ST QTR DEC | $609.3M |
EXPRESS REPORT: R2 FY26 1ST QTR DEC | $640.5M |
IV SUPPORT | $75K |
CHEMOTHERAPY COMPOUND FOR HV | $270K |
CHEMOTHERAPY COMPOUND JJP | $21K |
CHEMOTHERAPY COMPOUND SERVICE | — |
CHEMOTHERAPY COMPOUNDING SERVICE FOR NYH | $200K |
DALLAS VA PHARMACY COMPOUNDING FOR ONCOLOGY DRUGS | $1.2M |
AMARILLO VA PHARMACY COMPOUNDING FOR ONCOLOGY MEDICATIONS | $225K |
EXPRESS REPORT: R1 FY26 1ST QTR NOV | $526.4M |
EXPRESS REPORT: R2 FY26 1ST QTR NOV | $597.6M |
HAZARDOUS COMPOUNDING SERVICES | $300K |
ORDERING PERIOD 4 - STERILE COMPOUNDING | $100K |
CHEMO COMPOUNDING | $1.1M |
Source: USASpending.gov · Federal contract awards for UNH
| Jun 4, 2026 |
| Maria Elvira Salazar | Buy | Apr 22, 2026 |
| Gilbert Cisneros | Buy | Apr 14, 2026 |
| Alan Armstrong | Buy | Mar 27, 2026 |
| Richard Dean McCormick | Buy | Mar 19, 2026 |
Showing 8 of 96. STOCK Act disclosures lag up to 45 days.
Last Close
$420.74
2026-07-24
YTD
+25.1%
92% of 52-week range
